Panel recommends Merck continue cholesterol drug study
Nov 13 (Reuters) - Merck & Co said an independent data monitoring committee recommended that the company continue a study of its experimental cholesterol drug, anacetrapib.
The company said on Friday that the committee reviewed safety and efficacy data from the large study, including a futility analysis.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey)